Cargando…

Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency

Supplemental Digital Content is Available in the Text.

Detalles Bibliográficos
Autores principales:	Karlsson, Ulf, Repits, Johanna, Antonsson, Liselotte, Cederfjäll, Erik, Ljungberg, Bengt, Ålenius, Martin, Sabirsh, Alan, Gisslen, Magnus, Esbjörnsson, Joakim, Jansson, Marianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JAIDS Journal of Acquired Immune Deficiency Syndromes 2016
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770368/ https://www.ncbi.nlm.nih.gov/pubmed/26492461 http://dx.doi.org/10.1097/QAI.0000000000000873

Ejemplares similares

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc
por: Sierra, Saleta, et al.
Publicado: (2015)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain
por: Kelly, Kathleen M., et al.
Publicado: (2013)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression
por: Borggren, Marie, et al.
Publicado: (2008)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Genetic characterization of human immunodeficiency virus type 1 transmission in the Middle East and North Africa
por: Sallam, Malik, et al.
Publicado: (2017)

Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels
por: Sörstedt, Erik, et al.
Publicado: (2016)

Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge
por: Borggren, Marie, et al.
Publicado: (2011)

Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction
por: Ostrowski, Mario, et al.
Publicado: (2015)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Prevalence of HIV-1 pretreatment drug resistance among treatment naïve pregnant women in Bissau, Guinea Bissau
por: Wilhelmson, Sten, et al.
Publicado: (2018)

The HIV care continuum and HIV-1 drug resistance among female sex workers: a key population in Guinea-Bissau
por: Lindman, Jacob, et al.
Publicado: (2020)

Intra-Patient Evolution of HIV-2 Molecular Properties
por: Palm, Angelica A., et al.
Publicado: (2022)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock
por: Liu, Fu-Chao, et al.
Publicado: (2016)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
por: Pujari, Sanjay, et al.
Publicado: (2018)

CD4(+) T cells with an activated and exhausted phenotype distinguish immunodeficiency during aviremic HIV-2 infection
por: Buggert, Marcus, et al.
Publicado: (2016)

HIV entry blocked by maraviroc can cause an overestimation of viral load
por: Sloan, RD, et al.
Publicado: (2010)

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
por: Bregigeon, Sylvie, et al.
Publicado: (2010)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced
por: Cipriani, S, et al.
Publicado: (2012)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients
por: Piconi, Stefania, et al.
Publicado: (2016)

Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity
por: Legnani, L., et al.
Publicado: (2016)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
por: Ilomuanya, Margaret O., et al.
Publicado: (2020)

Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
por: Poveda, Eva, et al.
Publicado: (2010)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc
por: Rodriguez, Christophe, et al.
Publicado: (2015)

Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
por: Rose, Ronald, et al.
Publicado: (2022)

HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries
por: Esbjörnsson, Joakim, et al.
Publicado: (2016)

Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoprotein–Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2–Infected Individuals
por: Karlsson, Ingrid, et al.
Publicado: (2019)

Inverted CD8 T-Cell Exhaustion and Co-Stimulation Marker Balance Differentiate Aviremic HIV-2-Infected From Seronegative Individuals
por: Scharf, Lydia, et al.
Publicado: (2021)

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
por: Schlecht, Hans P, et al.
Publicado: (2008)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Lorenzen, Thore
Publicado: (2010)

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
por: Gulick, Roy M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5eimrmbkpn6ag28t6d11ma8lff